EUVIMEDEUVIMED entdecken
Crossref

Revealing the Action Mechanism of the FOXA 2‐ LAMC 2 Axis in Driving Cisplatin Resistance of Head and Neck Squamous Cell Carcinoma via Based Multi‐Omic Analysis and Experimental Validation

Caihong Liang iD, Hengtao Zhu, Yunfei Gao, Shuyue Yu, Guangda Liang, Cunyu Miao iD, Junjing Zhang, Hongqun Jiang

Chemical Biology & Drug Design · 2026-06 · 107 (6)

DOI: 10.1111/cbdd.70328 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemical Biology & Drug Design, online erschienen am 19.06.2026. Verfasst von Caihong Liang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, The Ist Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Cisplatin, Drug Resistance, Neoplasm, Head and Neck Neoplasms. Die Arbeit nennt 32 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cisplatin is a key treatment for head and neck squamous cell carcinoma (HNSCC), but the development of resistance severely limits its effectiveness. The molecular determinants underlying cisplatin resistance in HNSCC remain unclear. Multiple databases were used to screen the core genes related to cisplatin resistance in HNSCC patients. Tumor tissue samples from HNSCC patients were collected and the expression of FOXA2 was verified through various pathological tests to establish the correlation between FOXA2 expression and the clinical characteristics of the patients. The in vitro and patient‐derived organoids (PDOs) models were used to verify the regulatory effect of FOXA2 on the cisplatin resistance of HNSCC. Transcriptome sequencing combined with multi‐omics analysis demonstrated that LAMC2 is a downstream target of FOXA2 in regulating cisplatin resistance. Bioinformatic screening of cisplatin‐resistant cohorts revealed that FOXA2 was the only gene significantly associated with poor survival outcomes in TCGA‐HNSCC patients. Transcriptomic profiling and pathway enrichment analyses revealed the activation of the PI3K/AKT signaling cascade. We identified LAMC2 as a direct transcriptional target of FOXA2. Chromatin immunoprecipitation and luciferase reporter assays confirmed FOXA2 binding to the LAMC2 promoter, resulting in transcriptional activation. FOXA2‐mediated upregulation of LAMC2 increased PI3K and AKT phosphorylation, and LAMC2 overexpression reversed the impaired malignant phenotypes caused by FOXA2 silencing. In xenograft models and PDO systems, FOXA2 overexpression reduced responsiveness to cisplatin, whereas FOXA2 inhibition significantly increased therapeutic sensitivity. Our research has identified a previously unrecognized regulatory axis involving FOXA2, LAMC2, and PI3K/AKT, which plays a crucial role in the progression and resistance to cisplatin in HNSCC. Therefore, targeting the FOXA2‐LAMC2 axis may represent a novel therapeutic strategy to overcome cisplatin resistance in HNSCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsCisplatinDrug Resistance, NeoplasmHead and Neck NeoplasmsHepatocyte Nuclear Factor 3-betaSquamous Cell Carcinoma of Head and NeckAnimalsHumansCell Line, TumorMultiomicsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSignal Transduction

Stichwörter der Autor:innen

FOXA2LAMC2PI3Kcisplatin resistancehead and neck squamous cell carcinoma

Substanzen

Antineoplastic AgentsCisplatinFOXA2 protein, humanHepatocyte Nuclear Factor 3-betaPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-akt

Autor:innen und Institutionen

  • Department of Otolaryngology, The Ist Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
  • Department of Otolaryngology, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, China.
  • Institute of Medicine Nursing, Hubei University of Medicine, Shiyan, China.
  • Department of Otolaryngology, Jiangxi Provincial People's Hospital, Nanchang, China.
  • Department of Hepato-Biliary Surgery, Hohhot First Hospital, Hohhot, China.

ORCID-Profile: Caihong Liang, Cunyu Miao

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Liang, C., Zhu, H., Gao, Y., Yu, S., Liang, G., Miao, C., Zhang, J., & Jiang, H. (2026). Revealing the Action Mechanism of the FOXA 2‐ LAMC 2 Axis in Driving Cisplatin Resistance of Head and Neck Squamous Cell Carcinoma via Based Multi‐Omic Analysis and Experimental Validation. Chemical Biology & Drug Design, 107(6). https://doi.org/10.1111/cbdd.70328

Vancouver

Liang C, Zhu H, Gao Y, Yu S, Liang G, Miao C, et al. Revealing the Action Mechanism of the FOXA 2‐ LAMC 2 Axis in Driving Cisplatin Resistance of Head and Neck Squamous Cell Carcinoma via Based Multi‐Omic Analysis and Experimental Validation. Chemical Biology & Drug Design. 2026;107(6). doi:10.1111/cbdd.70328

BibTeX
@article{Liang2026,
  author = {Liang, Caihong and Zhu, Hengtao and Gao, Yunfei and Yu, Shuyue and Liang, Guangda and Miao, Cunyu and Zhang, Junjing and Jiang, Hongqun},
  title = {Revealing the Action Mechanism of the FOXA 2‐ LAMC 2 Axis in Driving Cisplatin Resistance of Head and Neck Squamous Cell Carcinoma via Based Multi‐Omic Analysis and Experimental Validation},
  journal = {Chemical Biology & Drug Design},
  year = {2026},
  volume = {107},
  number = {6},
  doi = {10.1111/cbdd.70328}
}
Kostenlos starten →